CLINICAL_TRIALS trial_result · 2010-11-04

Clinical Trial Update: SUTENT® In The First Line Treatment Of Renal Cell Carcinoma

A clinical trial evaluating SUTENT (sunitinib) as first-line treatment for renal cell carcinoma has completed, with results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Pfizer | Conditions: Renal Cell Carcinoma | Status: COMPLETED | Results posted: 2010-11-04